scholarly journals Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

Drugs in R&D ◽  
2021 ◽  
Author(s):  
Tal Y. Samuel ◽  
Tal Hasin ◽  
Israel Gotsman ◽  
Tanya Weitzman ◽  
Fanny Ben Ivgi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Coenzyme Q10 ◽  
Controlled Trial ◽  
Preserved Ejection Fraction ◽  
Double Blind ◽  
Double Blind Placebo

Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

2014 ◽  
Vol 10 (6) ◽  
pp. 693-698 ◽  
Author(s):  
Satnam Singh ◽  
Roger Beadle ◽  
Donnie Cameron ◽  
Amelia Rudd ◽  
Maggie Bruce ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Controlled Trial ◽  
Preserved Ejection Fraction ◽  
Double Blind ◽  
Double Blind Placebo

Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure

2003 ◽  
Vol 12 (3) ◽  
pp. 135-141 ◽  
Author(s):  
Anne Keogh ◽  
Steve Fenton ◽  
Christina Leslie ◽  
Christina Aboyoun ◽  
Peter Macdonald ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coenzyme Q10 ◽  
Controlled Trial ◽  
Systolic Heart Failure ◽  
Class Ii ◽  
Double Blind ◽  
Double Blind Placebo

Abstract 12897: Coenzyme Q10 in the Treatment of Heart Failure With Preserved Ejection Fraction: A Prospective, Randomized, Double-blind Trial

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Tal Y Samuel ◽  
Tal Hasin ◽  
Israel Gotsman ◽  
Tanya Weitsman ◽  
Fanny Ben Ivgi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Placebo Group ◽  
Ejection Fraction ◽  
Diastolic Function ◽  
Coenzyme Q10 ◽  
The Elderly ◽  
Left Ventricular ◽  
Volume Index ◽  
Preserved Ejection Fraction ◽  
Double Blind

Background: Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure (HF) in the elderly and is increasing in prevalence. No specific treatment for this condition appears to be effective. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production and reduced levels have been noted in HF. Previous studies have suggested a possible role for CoQ10 in the treatment of HF in particular in the elderly. Aim: To evaluate the effect of CoQ10 supplementation on diastolic function in patients with HFpEF. Methods: A prospective, randomized, double-blind, placebo-controlled trial. Inclusion criteria were age > 50 years, New York Heart Association class II-IV, ejection fraction > 50%, and evidence of impaired diastolic function defined as lateral e' < 0.09 cm/sec, average E/e' > 13 or average E/e' > 8 with additional markers of impaired diastolic function such as delayed relaxation (E/A < 0.5), elevated left atrial volume index (> 40ml / m 2 ) elevated left ventricular mass index ( > 122 gr/ m 2 ♀ or 149 gr/ m 2 ♂) or pulmonary hypertension. Patients with other forms of cardiomyopathies or treated with chronic renal replacement therapy were excluded. Echocardiographic studies and levels of N-terminal pro-B type natriuretic peptide (NT-proBNP) were completed at baseline and following 4 months of CoQ10 (300 mg daily) or placebo supplementation. Results: A total of 39 patients were enrolled, 19 patients in the CoQ10 and 20 patients in the placebo group. Groups were similar in baseline clinical characteristics. Compliance was high and similar between groups (average 208 ± 108 mg/day for the CoQ10 versus 212 ± 95 mg/day for the placebo group). No significant effect was observed on indices of diastolic function or NT-proBNP levels following 4 months of CoQ10 use. Conclusions: Treatment with CoQ10 did not affect indices of diastolic function or NT-proBNP levels in patients with HFpEF. Our study does not support the routine use of CoQ10 in patients with HFpEF.

Sign in / Sign up

Export Citation Format

Share Document